New Trial Alert: Three Alliance Trials Recently Opened

August 5, 2025

Alliance A012303: ShortStop-HER2: Shortened duration of adjuvant therapy in patients with early-stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade

Adrienne Waks, MD, of the Dana-Farber Cancer Institute, leads this phase III trial that compares six months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treat

• Read more

Alliance Presents Results from Phase III ATOMIC Trial Combining Atezolizumab with Chemotherapy for Patients with Stage III dMMR Colon Cancer at ASCO 2025

June 1, 2025

The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch re

• Read more

Alliance Trial Shows Dual Immunotherapy Improves Progression-Free Survival in Advanced Squamous Cell Skin Cancer

Avelumab Plus Cetuximab Combination Meets Primary Endpoint in Phase II Trial A091802, Presented at ASCO 2025 and Published in Journal of Clinical Oncology

May 31, 2025

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival

• Read more